electroCore, Inc. - Common Stock (ECOR)

Competitors to electroCore, Inc. - Common Stock (ECOR)

Cyclics

Cyclics develops alternative treatment therapies that focus on neuromodulation, similar to electroCore's focus on vagus nerve stimulation for conditions like migraines. Both companies target chronic pain and neurological disorders, but Cyclics has a broader portfolio of treatments in different stages of research and development, giving it a competitive edge in potential market applications.

NeuroPace, Inc. 

NeuroPace specializes in implantable neurostimulation devices targeted at epilepsy management, competing with electroCore’s transcutaneous devices. While both focus on neural modulation technologies, NeuroPace has the advantage of FDA approval for its devices, which establishes a market trust and user base that electroCore is still working to achieve.

Soterix Medical

Soterix Medical specializes in non-invasive neuromodulation devices similar to electroCore's offerings. By providing a repertoire of advanced technologies and a strong focus on research-backed protocols, Soterix Medical competes effectively, especially in clinical settings where established efficacy is critical for adoption.

Zynex, Inc. 

Zynex focuses on electrotherapy devices for pain management and rehabilitation, positioning itself within the same market space as electroCore. However, Zynex offers a more extensive range of already marketed products, enabling them to reach more patients while electroCore continues to develop its specific application for vagus nerve stimulation therapies.